沙利度胺治疗急性白血病的临床疗效及抗血管形成的观察  

Observation on the clinical effect and anti-angiogenesis effect in acute leukemia after treatment by thalidomide

作　　者：翟欣辉[1] 魏绪仓[1] 王一[1] 赵园[1] 连小赟[1] 张玎[1] 苗玉迪[1] 

机构地区：[1]陕西省人民医院血液科,西安市710068

出　　处：《实用医学杂志》2011年第23期4277-4279,共3页The Journal of Practical Medicine

基　　金：陕西省科技攻关基金资助项目(编号:2010K14-02-14)

摘　　要：目的:观察沙利度胺联合化疗治疗急性白血病临床疗效及对血浆血管内皮生长因子(VEGF)、血管内皮生长因子受体(VEGFR)、碱性成纤维细胞生长因子(bFGF)、骨髓微血管密度(MVD)的影响。方法:急性白血病36例,分为实验组及对照组各18例。每组均常规化疗,实验组同时口服沙利度胺100mg/d。治疗前及治疗后8周采集外周血双抗体夹心酶联免疫吸附法(ELISA)检测血浆VEGF、VEGFR、bFGF及MVD测定。结果:实验组与对照组治疗的有效率分别为88.9%(16/18)、77.8%(14/18),差异有统计学意义(P<0.05)。实验组与对照组治疗后血浆VEGF、VEGFR、MVD[(211.74±36.72)pg/mLvs.(288.02±31.77)pg/mL;[(1359.71±390.24)pg/mLvs.(1753.89±337.04)pg/mL;(8.30±4.57)n/HPvs.(14.78±2.76)n/HP]相比差异有统计学意义(均P<0.05),血浆[bFGF(2.09±0.17)ng/mLvs.(2.11±0.31)ng/mL]相比差异无统计学意义(P>0.05)。结论:沙利度胺联合化疗可提高急性白血病的缓解率,可能通过抑制血浆VEGF及其受体表达、减少MVD而发挥抗白血病作用。Objective To observe the clinical effect and the influence of the level of plasma vascular endothelial growth factor （VEGF）, vascular endothelial growth factor receptor （VEGFR）, basic fibroblast growth factor （bFGF） and bone marrow mierovaseular density （MVD） in acute leukemia after treatment by thalidomide combined with chemotherapy. Methods 36 cases of acute leukemia patients were randomly divided into experimental group and control group by 18 cases each. Each group was treated with chemotherapy meanwhile in the experimental group additional thalidomide 100 mg/day were taken orally. Before treatment and 8 weeks after treatment, plasma were collected for the detection of VEGF, VEGFR, bFGF and MVD by double antibody sandwich enzyme-linked immunosorbent assay （ELISA）. Results The ratio of effective were 88.9%（16/18）, 77.8%（14/18） respectively in experimental group and control group, the difference was statistically significant （P 〈 0.05）. The difference of the levels of plasma VEGF, VEGFR and MVD in experimental group and control group after treatment [ （211.74±36.72）pg/mL vs. （288.02 ± 31.77）pg/mL; [ （ 1 359.71 ±390.24）pg/mL vs. （ 1 753.89±337.04）pg/mL; （ 8.30 ± 4.57 ） n/HP vs. （ 14.78 ± 2.76） n/HP ] was statistically significant （all P 〈 0.05 ）, while bFGF （2.09 ± 0.17）ng/mL vs. （2.11 ± 0.31）ng/mL]was not statistically significant （P 〉 0.05）. Conclusion Thalidomide combined with chemotherapy can improve the remission rate in acute leukemia, its mechanism may be conduced through inhibiting the plasma levels of VEGF and VEGFR to decrease MVD, then take effect on anti-leukemia.

关 键 词：沙利度胺 血管内皮生长因子 碱性成纤维细胞生长因子 骨髓微血管密度 

分 类 号：R733.71[医药卫生—肿瘤]